Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
16 juil. 2024 08h37 HE
|
Trethera Corporation
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Synthetic Immunology Market Report 2024 with Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
04 juil. 2024 07h28 HE
|
Research and Markets
Dublin, July 04, 2024 (GLOBE NEWSWIRE) -- The "Synthetic Immunology Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Synthetic Immunology Market is...
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
03 juil. 2024 05h00 HE
|
Medigene AG
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Alumis Announces Pricing of Initial Public Offering
27 juin 2024 23h57 HE
|
Alumis Inc.
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
27 juin 2024 06h30 HE
|
Medigene AG
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
21 juin 2024 04h30 HE
|
Medigene AG
Planegg/Martinsried, June 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
14 juin 2024 03h00 HE
|
Janssen Cilag International NV
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of...
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
03 juin 2024 11h00 HE
|
Biolojic Design
Biolojic Design Enters into Multi-Target Drug Discovery Collaboration
with Merck KGaA, Darmstadt, Germany in oncology and immunology
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
31 mai 2024 01h05 HE
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
31 mai 2024 01h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...